CDE Detailed Report

Disease: Parkinson's Disease
Sub-Domain: Quality of Life/Patient Reported Outcomes
CRF: Parkinson's Disease Quality of Life Scale (PDQUALIF)

Displaying 1 - 33 of 33
CDE ID CDE Name Variable Name Definition Short Description Question Text Permissible Values Description Data Type Disease Specific Instructions Disease Specific Reference Population Classification (e.g., Core) Version Number Version Date CRF Name (CRF Module / Guideline) Sub Domain Name Domain Name Size Input Restrictions Min Value Max Value Measurement Type External Id Loinc External Id Snomed External Id caDSR External Id CDISC
C17377 Parkinson's Disease Quality of Life (PDQUALIF) - independent important scale PDQUALIFIndepImportScale Rating scale for feeling important to maintain independence as part of Parkinson's Disease Quality of Life (PDQUALIF) form Rating scale for feeling important to maintain independence as part of Parkinson's Disease Quality of Life (PDQUALIF) form Maintaining my independence is important to me Never;Rarely;Sometimes;Frequently;Always Never;Rarely;Sometimes;Frequently;Always Alphanumeric

Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.

PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237. Adult Supplemental-Highly Recommended 3.00 2013-07-18 09:11:50.26 Parkinson's Disease Quality of Life Scale (PDQUALIF) Quality of Life/Patient Reported Outcomes Outcomes and End Points

Single Pre-Defined Value Selected

C17388 Parkinson's Disease Quality of Life (PDQUALIF) - fatigue participation problem 7 days scale PDQUALIFFatigPartProb7DScale Rating scale for problem in participation in activities, household chores, shopping or yard work due to fatigue in past 7 days as part of Parkinson's Disease Quality of Life (PDQUALIF) form Rating scale for problem in participation in activities, household chores, shopping or yard work due to fatigue in past 7 days as part of Parkinson's Disease Quality of Life (PDQUALIF) form In the past 7 days, fatigue makes participation in activities, household chores, shopping or yard work a problem for me Always;Frequently;Sometimes;Rarely;Never Always;Frequently;Sometimes;Rarely;Never Alphanumeric

Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.

PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237. Adult Supplemental-Highly Recommended 3.00 2013-07-18 09:11:50.26 Parkinson's Disease Quality of Life Scale (PDQUALIF) Quality of Life/Patient Reported Outcomes Outcomes and End Points

Single Pre-Defined Value Selected

C17367 Parkinson's Disease Quality of Life (PDQUALIF) - aching limb scale PDQUALIFAcheLimbScale Rating Scale for having aching/burning/coldness/numbness in the hand/feet as part of Parkinson's Disease Quality of Life (PDQUALIF) form Rating Scale for having aching/burning/coldness/numbness in the hand/feet as part of Parkinson's Disease Quality of Life (PDQUALIF) form I have aching/burning/coldness/numbness in my hand/feet Never;Rarely;Sometimes;Frequently;Always Never;Rarely;Sometimes;Frequently;Always Alphanumeric

Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.

PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237. Adult Supplemental-Highly Recommended 3.00 2013-07-18 09:11:50.26 Parkinson's Disease Quality of Life Scale (PDQUALIF) Quality of Life/Patient Reported Outcomes Outcomes and End Points

Single Pre-Defined Value Selected

C17378 Parkinson's Disease Quality of Life (PDQUALIF) - difficulty adjust change scale PDQUALIFDiffcltAdjtChngScale Rating scale for feeling difficult to adjust to the changes which have taken place in the body as part of Parkinson's Disease Quality of Life (PDQUALIF) form Rating scale for feeling difficult to adjust to the changes which have taken place in the body as part of Parkinson's Disease Quality of Life (PDQUALIF) form It has been difficult to adjust to the changes which have taken place in my body Very;Moderately;Somewhat;Slightly;Not at all Very;Moderately;Somewhat;Slightly;Not at all Alphanumeric

Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.

PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237. Adult Supplemental-Highly Recommended 3.00 2013-07-18 09:11:50.26 Parkinson's Disease Quality of Life Scale (PDQUALIF) Quality of Life/Patient Reported Outcomes Outcomes and End Points

Single Pre-Defined Value Selected

C17389 Parkinson's Disease Quality of Life (PDQUALIF) - usual share interfered 7 days scale PDQUALIFUsuSharInterf7DScale Rating scale for the ability to do usual share in the home interfered by the Parkinson's symptoms in past 7 days as part of Parkinson's Disease Quality of Life (PDQUALIF) form Rating scale for the ability to do usual share in the home interfered by the Parkinson's symptoms in past 7 days as part of Parkinson's Disease Quality of Life (PDQUALIF) form In the past 7 days, my Parkinson's symptoms interfere with my ability to do my usual share in the home Always;Frequently;Sometimes;Rarely;Never Always;Frequently;Sometimes;Rarely;Never Alphanumeric

Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.

PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237. Adult Supplemental-Highly Recommended 3.00 2013-07-18 09:11:50.26 Parkinson's Disease Quality of Life Scale (PDQUALIF) Quality of Life/Patient Reported Outcomes Outcomes and End Points

Single Pre-Defined Value Selected

C17368 Parkinson's Disease Quality of Life (PDQUALIF) - difficulty bladder control scale PDQUALIFDiffcltBladContScale Rating scale for difficulty with bladder control (frequency, urgency, inability) as part of Parkinson's Disease Quality of Life (PDQUALIF) form Rating scale for difficulty with bladder control (frequency, urgency, inability) as part of Parkinson's Disease Quality of Life (PDQUALIF) form I have difficulty with bladder control (frequency, urgency, inability) Never;Rarely;Sometimes;Frequently;Always Never;Rarely;Sometimes;Frequently;Always Alphanumeric

Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.

PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237. Adult Supplemental-Highly Recommended 3.00 2013-07-18 09:11:50.26 Parkinson's Disease Quality of Life Scale (PDQUALIF) Quality of Life/Patient Reported Outcomes Outcomes and End Points

Single Pre-Defined Value Selected

C17379 Parkinson's Disease Quality of Life (PDQUALIF) - social life not affected scale PDQUALIFSocLfNotAffctedScale Rating scale for feeling that the social life has not been affected by the Parkinson's symptoms as part of Parkinson's Disease Quality of Life (PDQUALIF) form Rating scale for feeling that the social life has not been affected by the Parkinson's symptoms as part of Parkinson's Disease Quality of Life (PDQUALIF) form My Parkinson's symptoms have not affected my social life Strongly Agree;Somewhat Agree;Agree;Somewhat disagree;Strongly Disagree Strongly Agree;Somewhat Agree;Agree;Somewhat disagree;Strongly Disagree Alphanumeric

Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.

PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237. Adult Supplemental-Highly Recommended 3.00 2013-07-18 09:11:50.26 Parkinson's Disease Quality of Life Scale (PDQUALIF) Quality of Life/Patient Reported Outcomes Outcomes and End Points

Single Pre-Defined Value Selected

C17390 Parkinson's Disease Quality of Life (PDQUALIF) - not sleep with spouse night 7 days scale PDQUALIFNotSlpNghtWSpous7DScl Rating scale for keeping you from sleeping with the spouse/partner due to the nighttime symptoms in past 7 days as part of Parkinson's Disease Quality of Life (PDQUALIF) form Rating scale for keeping you from sleeping with the spouse/partner due to the nighttime symptoms in past 7 days as part of Parkinson's Disease Quality of Life (PDQUALIF) form In the past 7 days, my nighttime symptoms keep me from sleeping with my spouse/partner Everyday;5-6 Days;3-4 Days;1-2 days;Never Everyday;5-6 Days;3-4 Days;1-2 days;Never Alphanumeric

Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.

PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237. Adult Supplemental-Highly Recommended 3.00 2013-07-18 09:11:50.26 Parkinson's Disease Quality of Life Scale (PDQUALIF) Quality of Life/Patient Reported Outcomes Outcomes and End Points

Single Pre-Defined Value Selected

C17369 Parkinson's Disease Quality of Life (PDQUALIF) - constipation scale PDQUALIFConstipScale Rating scale for constipation problem as part of Parkinson's Disease Quality of Life (PDQUALIF) form Rating scale for constipation problem as part of Parkinson's Disease Quality of Life (PDQUALIF) form Constipation is a problem Never;Rarely;Sometimes;Frequently;Always Never;Rarely;Sometimes;Frequently;Always Alphanumeric

Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.

PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237. Adult Supplemental-Highly Recommended 3.00 2013-07-18 09:11:50.26 Parkinson's Disease Quality of Life Scale (PDQUALIF) Quality of Life/Patient Reported Outcomes Outcomes and End Points

Single Pre-Defined Value Selected

C17380 Parkinson's Disease Quality of Life (PDQUALIF) - travel important scale PDQUALIFTravelImportScale Rating scale for feeling that travel remains an important part of leisure activities as part of Parkinson's Disease Quality of Life (PDQUALIF) form Rating scale for feeling that travel remains an important part of leisure activities as part of Parkinson's Disease Quality of Life (PDQUALIF) form Travel remains an important part of my leisure activities Strongly Agree;Somewhat Agree;Agree;Somewhat disagree;Strongly Disagree Strongly Agree;Somewhat Agree;Agree;Somewhat disagree;Strongly Disagree Alphanumeric

Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.

PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237. Adult Supplemental-Highly Recommended 3.00 2013-07-18 09:11:50.26 Parkinson's Disease Quality of Life Scale (PDQUALIF) Quality of Life/Patient Reported Outcomes Outcomes and End Points

Single Pre-Defined Value Selected

C17391 Parkinson's Disease Quality of Life (PDQUALIF) - driving interfered 7 days scale PDQUALIFDrivInterf7DScale Rating scale for interfered driving ability due to Parkinson's symptoms as part of Parkinson's Disease Quality of Life (PDQUALIF) form Rating scale for interfered driving ability due to Parkinson's symptoms as part of Parkinson's Disease Quality of Life (PDQUALIF) form In the past 7 days, my Parkinson's symptoms have interfered with my driving ability Doesn't Apply;Rarely;Sometimes;Frequently;Constantly Doesn't Apply;Rarely;Sometimes;Frequently;Constantly Alphanumeric

Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.

PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237. Adult Supplemental-Highly Recommended 3.00 2013-07-18 09:11:50.26 Parkinson's Disease Quality of Life Scale (PDQUALIF) Quality of Life/Patient Reported Outcomes Outcomes and End Points

Single Pre-Defined Value Selected

C17370 Parkinson's Disease Quality of Life (PDQUALIF) - trouble fall asleep scale PDQUALIFTroubFallAslpScale Rating scale for trouble falling asleep, or waking early due to the Parkinson's symptoms as part of Parkinson's Disease Quality of Life (PDQUALIF) form Rating scale for trouble falling asleep, or waking early due to the Parkinson's symptoms as part of Parkinson's Disease Quality of Life (PDQUALIF) form My Parkinson's symptoms cause me to have trouble falling asleep, or waking early Never;Rarely;Sometimes;Frequently;Always Never;Rarely;Sometimes;Frequently;Always Alphanumeric

Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.

PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237. Adult Supplemental-Highly Recommended 3.00 2013-07-18 09:11:50.26 Parkinson's Disease Quality of Life Scale (PDQUALIF) Quality of Life/Patient Reported Outcomes Outcomes and End Points

Single Pre-Defined Value Selected

C17381 Parkinson's Disease Quality of Life (PDQUALIF) - family role affected scale PDQUALIFFamRoleAffctedScale Rating scale for family role and relationship affected by the Parkinson's symptoms as part of Parkinson's Disease Quality of Life (PDQUALIF) form Rating scale for family role and relationship affected by the Parkinson's symptoms as part of Parkinson's Disease Quality of Life (PDQUALIF) form My Parkinson's symptoms have affected my family role and relationship Strongly Agree;Somewhat Agree;Agree;Somewhat disagree;Strongly Disagree Strongly Agree;Somewhat Agree;Agree;Somewhat disagree;Strongly Disagree Alphanumeric

Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.

PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237. Adult Supplemental-Highly Recommended 3.00 2013-07-18 09:11:50.26 Parkinson's Disease Quality of Life Scale (PDQUALIF) Quality of Life/Patient Reported Outcomes Outcomes and End Points

Single Pre-Defined Value Selected

C17392 Parkinson's Disease Quality of Life (PDQUALIF) - financial strain 7 days scale PDQUALIFFinancStrain7DaysScale Rating scale for a financial strain due to the illness in past 7 days as part of Parkinson's Disease Quality of Life (PDQUALIF) form Rating scale for a financial strain due to the illness in past 7 days as part of Parkinson's Disease Quality of Life (PDQUALIF) form In the past 7 days, my illness has caused a financial strain for me and my family Doesn't Apply;Rarely a concern;Sometimes;Frequently;Constantly Doesn't Apply;Rarely a concern;Sometimes;Frequently;Constantly Alphanumeric

Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.

PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237. Adult Supplemental-Highly Recommended 3.00 2013-07-18 09:11:50.26 Parkinson's Disease Quality of Life Scale (PDQUALIF) Quality of Life/Patient Reported Outcomes Outcomes and End Points

Single Pre-Defined Value Selected

C17371 Parkinson's Disease Quality of Life (PDQUALIF) - trouble stay asleep scale PDQUALIFTroubStayAslpScale Rating scale for trouble staying asleep as part of Parkinson's Disease Quality of Life (PDQUALIF) form Rating scale for trouble staying asleep as part of Parkinson's Disease Quality of Life (PDQUALIF) form I have trouble staying asleep Never;Rarely;Sometimes;Frequently;Always Never;Rarely;Sometimes;Frequently;Always Alphanumeric

Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.

PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237. Adult Supplemental-Highly Recommended 3.00 2013-07-18 09:11:50.26 Parkinson's Disease Quality of Life Scale (PDQUALIF) Quality of Life/Patient Reported Outcomes Outcomes and End Points

Single Pre-Defined Value Selected

C17382 Parkinson's Disease Quality of Life (PDQUALIF) - away from social scale PDQUALIFAwyFrmSocScale Rating scale for staying away from social gatherings due to the Parkinson's symptoms as part of Parkinson's Disease Quality of Life (PDQUALIF) form Rating scale for staying away from social gatherings due to the Parkinson's symptoms as part of Parkinson's Disease Quality of Life (PDQUALIF) form My Parkinson's symptoms cause me to stay away from social gatherings Strongly Agree;Somewhat Agree;Agree;Somewhat disagree;Strongly Disagree Strongly Agree;Somewhat Agree;Agree;Somewhat disagree;Strongly Disagree Alphanumeric

Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.

PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237. Adult Supplemental-Highly Recommended 3.00 2013-07-18 09:11:50.26 Parkinson's Disease Quality of Life Scale (PDQUALIF) Quality of Life/Patient Reported Outcomes Outcomes and End Points

Single Pre-Defined Value Selected

C17361 Parkinson's Disease Quality of Life (PDQUALIF) - lightheaded scale PDQUALIFLghtHdScale Rating scale for lightheaded symptom caused by changing positions (lying to standing, or sitting to standing) as part of Parkinson's Disease Quality of Life (PDQUALIF) form Rating scale for lightheaded symptom caused by changing positions (lying to standing, or sitting to standing) as part of Parkinson's Disease Quality of Life (PDQUALIF) form Changing positions causes me to become lightheaded (lying to standing, or sitting to standing) Never;Rarely;Sometimes;Occasionally;Always Never;Rarely;Sometimes;Occasionally;Always Alphanumeric

Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.

PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237. Adult Supplemental-Highly Recommended 3.00 2013-07-18 09:11:50.26 Parkinson's Disease Quality of Life Scale (PDQUALIF) Quality of Life/Patient Reported Outcomes Outcomes and End Points

Single Pre-Defined Value Selected

C17393 Parkinson's Disease Quality of Life (PDQUALIF) - symptoms 7days compare 6-months scale PDQUALIFSymp7DComp6MScale Rating scale for the Parkinson's symptoms in past 7 days compared to 6 months ago as part of Parkinson's Disease Quality of Life (PDQUALIF) form Rating scale for the Parkinson's symptoms in past 7 days compared to 6 months ago as part of Parkinson's Disease Quality of Life (PDQUALIF) form In the past 7 days compared to 6 months ago, my Parkinson's symptoms are Much better;Somewhat better;About the same;Somewhat worse;Much Worse Much better;Somewhat better;About the same;Somewhat worse;Much Worse Alphanumeric

Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.

PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237. Adult Supplemental-Highly Recommended 3.00 2013-07-18 09:11:50.26 Parkinson's Disease Quality of Life Scale (PDQUALIF) Quality of Life/Patient Reported Outcomes Outcomes and End Points

Single Pre-Defined Value Selected

C17372 Parkinson's Disease Quality of Life (PDQUALIF) - positive outlook scale PDQUALIFPositvOutlkScale Rating scale for maintaining a positive outlook due to the Parkinson's symptoms as part of Parkinson's Disease Quality of Life (PDQUALIF) form Rating scale for maintaining a positive outlook due to the Parkinson's symptoms as part of Parkinson's Disease Quality of Life (PDQUALIF) form My Parkinson's symptoms make it hard to maintain a positive outlook Never;Rarely;Sometimes;Frequently;Always Never;Rarely;Sometimes;Frequently;Always Alphanumeric

Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.

PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237. Adult Supplemental-Highly Recommended 3.00 2013-07-18 09:11:50.26 Parkinson's Disease Quality of Life Scale (PDQUALIF) Quality of Life/Patient Reported Outcomes Outcomes and End Points

Single Pre-Defined Value Selected

C17383 Parkinson's Disease Quality of Life (PDQUALIF) - family friends view change scale PDQUALIFFamFridViewChngScale Rating scale for feeing that your spouse/children/friends' view of you has changed because of your illness as part of Parkinson's Disease Quality of Life (PDQUALIF) form Rating scale for feeing that your spouse/children/friends' view of you has changed because of your illness as part of Parkinson's Disease Quality of Life (PDQUALIF) form My spouse/children/friends' view of me has changed because of my illness Strongly Agree;Somewhat Agree;Agree;Somewhat disagree;Strongly Disagree Strongly Agree;Somewhat Agree;Agree;Somewhat disagree;Strongly Disagree Alphanumeric

Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.

PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237. Adult Supplemental-Highly Recommended 3.00 2013-07-18 09:11:50.26 Parkinson's Disease Quality of Life Scale (PDQUALIF) Quality of Life/Patient Reported Outcomes Outcomes and End Points

Single Pre-Defined Value Selected

C17362 Parkinson's Disease Quality of Life (PDQUALIF) - trouble balance scale PDQUALIFTroubBalScale Rating scale for trouble keeping balance while walking as part of Parkinson's Disease Quality of Life (PDQUALIF) form Rating scale for trouble keeping balance while walking as part of Parkinson's Disease Quality of Life (PDQUALIF) form When walking, I have trouble keeping my balance Never;Rarely;Sometimes;Occasionally;Always Never;Rarely;Sometimes;Occasionally;Always Alphanumeric

Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.

PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237. Adult Supplemental-Highly Recommended 3.00 2013-07-18 09:11:50.26 Parkinson's Disease Quality of Life Scale (PDQUALIF) Quality of Life/Patient Reported Outcomes Outcomes and End Points

Single Pre-Defined Value Selected

C17373 Parkinson's Disease Quality of Life (PDQUALIF) - feel burden scale PDQUALIFFeelBurdScale Rating scale for feeling a burden to other people due to the Parkinson's symptoms as part of Parkinson's Disease Quality of Life (PDQUALIF) form Rating scale for feeling a burden to other people due to the Parkinson's symptoms as part of Parkinson's Disease Quality of Life (PDQUALIF) form My Parkinson's symptoms cause me to feel like a burden to other people Never;Rarely;Sometimes;Frequently;Always Never;Rarely;Sometimes;Frequently;Always Alphanumeric

Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.

PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237. Adult Supplemental-Highly Recommended 3.00 2013-07-18 09:11:50.26 Parkinson's Disease Quality of Life Scale (PDQUALIF) Quality of Life/Patient Reported Outcomes Outcomes and End Points

Single Pre-Defined Value Selected

C17384 Parkinson's Disease Quality of Life (PDQUALIF) - less sexually desirable scale PDQUALIFLesSexDesirblScale Rating scale for feeling of less sexually desirable because of the illness as part of Parkinson's Disease Quality of Life (PDQUALIF) form Rating scale for feeling of less sexually desirable because of the illness as part of Parkinson's Disease Quality of Life (PDQUALIF) form I feel I am less sexually desirable because of my illness Strongly Agree;Somewhat Agree;Agree;Somewhat disagree;Strongly Disagree Strongly Agree;Somewhat Agree;Agree;Somewhat disagree;Strongly Disagree Alphanumeric

Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.

PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237. Adult Supplemental-Highly Recommended 3.00 2013-07-18 09:11:50.26 Parkinson's Disease Quality of Life Scale (PDQUALIF) Quality of Life/Patient Reported Outcomes Outcomes and End Points

Single Pre-Defined Value Selected

C17363 Parkinson's Disease Quality of Life (PDQUALIF) - difficult swallowing scale PDQUALIFDiffcltSwallScale Rating scale for difficulty swallowing while eating or drinking liquids as part of Parkinson's Disease Quality of Life (PDQUALIF) form Rating scale for difficulty swallowing while eating or drinking liquids as part of Parkinson's Disease Quality of Life (PDQUALIF) form When eating or drinking liquids, I have difficulty swallowing Never;Rarely;Sometimes;Frequently;Always Never;Rarely;Sometimes;Frequently;Always Alphanumeric

Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.

PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237. Adult Supplemental-Highly Recommended 3.00 2013-07-18 09:11:50.26 Parkinson's Disease Quality of Life Scale (PDQUALIF) Quality of Life/Patient Reported Outcomes Outcomes and End Points

Single Pre-Defined Value Selected

C17374 Parkinson's Disease Quality of Life (PDQUALIF) - affected social life scale PDQUALIFSocLfAffctedScale Rating scale for affected social life by Parkinson's symptoms as part of Parkinson's Disease Quality of Life (PDQUALIF) form Rating scale for affected social life by Parkinson's symptoms as part of Parkinson's Disease Quality of Life (PDQUALIF) form My Parkinson's symptoms have affected my social life Never;Rarely;Sometimes;Frequently;Always Never;Rarely;Sometimes;Frequently;Always Alphanumeric

Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.

PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237. Adult Supplemental-Highly Recommended 3.00 2013-07-18 09:11:50.26 Parkinson's Disease Quality of Life Scale (PDQUALIF) Quality of Life/Patient Reported Outcomes Outcomes and End Points

Single Pre-Defined Value Selected

C17385 Parkinson's Disease Quality of Life (PDQUALIF) - hygiene independence 7 days scale PDQUALIFHygienIndep7DaysScale Rating scale for personal hygiene (bathing, hair care, make up, shaving, or toileting) independence in past 7 days as part of Parkinson's Disease Quality of Life (PDQUALIF) form Rating scale for personal hygiene (bathing, hair care, make up, shaving, or toileting) independence in past 7 days as part of Parkinson's Disease Quality of Life (PDQUALIF) form In the past 7 days, in my personal hygiene (bathing, hair care, make up, shaving, or toileting) I have been independent Everyday;5-6 Days;3-4 Days;1-2 days;Never Everyday;5-6 Days;3-4 Days;1-2 days;Never Alphanumeric

Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.

PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237. Adult Supplemental-Highly Recommended 3.00 2013-07-18 09:11:50.26 Parkinson's Disease Quality of Life Scale (PDQUALIF) Quality of Life/Patient Reported Outcomes Outcomes and End Points

Single Pre-Defined Value Selected

C17364 Parkinson's Disease Quality of Life (PDQUALIF) - communication ability scale PDQUALIFCommunAbScale Rating scale for ability of communication with people affected by illness as part of Parkinson's Disease Quality of Life (PDQUALIF) form Rating scale for ability of communication with people affected by illness as part of Parkinson's Disease Quality of Life (PDQUALIF) form My Parkinson's symptoms affect my ability to communicate with people Never;Rarely;Sometimes;Frequently;Always Never;Rarely;Sometimes;Frequently;Always Alphanumeric

Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.

PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237. Adult Supplemental-Highly Recommended 3.00 2013-07-18 09:11:50.26 Parkinson's Disease Quality of Life Scale (PDQUALIF) Quality of Life/Patient Reported Outcomes Outcomes and End Points

Single Pre-Defined Value Selected

C17375 Parkinson's Disease Quality of Life (PDQUALIF) - worry future scale PDQUALIFWorryFutScale Rating scale for worrying about what the future has in store as part of Parkinson's Disease Quality of Life (PDQUALIF) form Rating scale for worrying about what the future has in store as part of Parkinson's Disease Quality of Life (PDQUALIF) form I worry about what the future has in store Never;Rarely;Sometimes;Frequently;Always Never;Rarely;Sometimes;Frequently;Always Alphanumeric

Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.

PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237. Adult Supplemental-Highly Recommended 3.00 2013-07-18 09:11:50.26 Parkinson's Disease Quality of Life Scale (PDQUALIF) Quality of Life/Patient Reported Outcomes Outcomes and End Points

Single Pre-Defined Value Selected

C17386 Parkinson's Disease Quality of Life (PDQUALIF) - food preparation eating independent 7 days scale PDQUALIFFoodPrepEatIndep7DScl Rating scale for preparing and eating independently in the past 7 days as part of Parkinson's Disease Quality of Life (PDQUALIF) form Rating scale for preparing and eating independently in the past 7 days as part of Parkinson's Disease Quality of Life (PDQUALIF) form In the past 7 days, in food preparation or eating I am independent Everyday;5-6 Days;3-4 Days;1-2 days;Never Everyday;5-6 Days;3-4 Days;1-2 days;Never Alphanumeric

Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.

PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237. Adult Supplemental-Highly Recommended 3.00 2013-07-18 09:11:50.26 Parkinson's Disease Quality of Life Scale (PDQUALIF) Quality of Life/Patient Reported Outcomes Outcomes and End Points

Single Pre-Defined Value Selected

C17365 Parkinson's Disease Quality of Life (PDQUALIF) - night wakeup bathroom scale PDQUALIFNghtWakeBRScale Rating scale for waking up at night due to the need to go to the bathroom as part of Parkinson's Disease Quality of Life (PDQUALIF) form Rating scale for waking up at night due to the need to go to the bathroom as part of Parkinson's Disease Quality of Life (PDQUALIF) form The need to go to the bathroom wakes me in the night Never;Rarely;Sometimes;Frequently;Always Never;Rarely;Sometimes;Frequently;Always Alphanumeric

Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.

PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237. Adult Supplemental-Highly Recommended 3.00 2013-07-18 09:11:50.26 Parkinson's Disease Quality of Life Scale (PDQUALIF) Quality of Life/Patient Reported Outcomes Outcomes and End Points

Single Pre-Defined Value Selected

C17376 Parkinson's Disease Quality of Life (PDQUALIF) - difficulty ask help scale PDQUALIFAskHelpScale Rating scale for feeling difficult to ask others for help as part of Parkinson's Disease Quality of Life (PDQUALIF) form Rating scale for feeling difficult to ask others for help as part of Parkinson's Disease Quality of Life (PDQUALIF) form Asking others for help is difficult for me Never;Rarely;Sometimes;Frequently;Always Never;Rarely;Sometimes;Frequently;Always Alphanumeric

Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.

PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237. Adult Supplemental-Highly Recommended 3.00 2013-07-18 09:11:50.26 Parkinson's Disease Quality of Life Scale (PDQUALIF) Quality of Life/Patient Reported Outcomes Outcomes and End Points

Single Pre-Defined Value Selected

C17387 Parkinson's Disease Quality of Life (PDQUALIF) - writing speaking problem 7 days scale PDQUALIFWrtSpkProb7DScale Rating scale for a problem in written or spoken communication in past 7 days as part of Parkinson's Disease Quality of Life (PDQUALIF) form Rating scale for a problem in written or spoken communication in past 7 days as part of Parkinson's Disease Quality of Life (PDQUALIF) form In the past 7 days, written or spoken communication is a problem for me Never;Rarely;Sometimes;Frequently;Always Never;Rarely;Sometimes;Frequently;Always Alphanumeric

Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.

PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237. Adult Supplemental-Highly Recommended 3.00 2013-07-18 09:11:50.26 Parkinson's Disease Quality of Life Scale (PDQUALIF) Quality of Life/Patient Reported Outcomes Outcomes and End Points

Single Pre-Defined Value Selected

C17366 Parkinson's Disease Quality of Life (PDQUALIF) - affection ability scale PDQUALIFAffectnAbScale Rating scale for ability to show affection in intimate or sexual ways affected by the Parkinson's symptoms as part of Parkinson's Disease Quality of Life (PDQUALIF) form Rating scale for ability to show affection in intimate or sexual ways affected by the Parkinson's symptoms as part of Parkinson's Disease Quality of Life (PDQUALIF) form My Parkinson's symptoms affect my ability to show affection in intimate or sexual ways Never;Rarely;Sometimes;Frequently;Always Never;Rarely;Sometimes;Frequently;Always Alphanumeric

Select the answer which best describes your personal situation. Note: If at least one CDE was selected from a copyright- or trademark-protected instrument/scale then all of the CDEs from that instrument/scale are included in this report. The instrument may not be reproduced or translated in whole or in part without the express written permission of the lead author, Mickie Welsh. See http://pdqualif.com for full terms and use and licensing information.

PDQUALIF M. Welsh and the Parkinson Study Group(TM), 1996. Reprinted with permission, Mickie Welsh. Mickie Welsh and the Parkinson Study Group(TM) are the copyright holders for the PDQUALIF. Welsh M., McDermott M.P., et al. (2003). Development and testing of the Parkinson's Disease Quality of Life Scale (PDQUALIF). Mov Disord 18(6):637-645. Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol, 59:1937-1943. Holloway R.G., Shoulson I., Fahn S, et al. (2004). Pramipexole vs. Levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch Neurol, 61:1044-1053. Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62:241-248. Fahn S., Parkinson Study Group. (2005). Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol, 252(Suppl 4):IV37-IV42. Brown C.A., Cheng E.M., et al. (2009). SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures. Qual Life Res, 18:1219-1237. Adult Supplemental-Highly Recommended 3.00 2013-07-18 09:11:50.26 Parkinson's Disease Quality of Life Scale (PDQUALIF) Quality of Life/Patient Reported Outcomes Outcomes and End Points

Single Pre-Defined Value Selected

CSV